RPS29P25

Across TCGA pan-cancer cohorts, RPS29P25 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated RPS29P25 data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RPS29P25 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPS29P25 expression acts as an unfavorable survival marker.

OV, MESO, and HNSC are the cancer types where RPS29P25 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	II,III,IV	0.028	0.844	<.001	144	view →
MESO	OS	Tertile	III,IV	0.069	0.580	<.001	108	view →
HNSC	OS	Tertile	All	0.327	0.663	.023	81	view →
BRCA	OS	Tertile	All	0.668	0.924	.011	48	view →
GBM	OS	Tertile	All	0.026	0.416	<.001	36	view →
STAD	OS	Tertile	III,IV	0.170	0.524	.031	27	view →
LUAD	OS	Tertile	All	0.510	0.835	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPS29P25–OV (OS)

Open the OV breakdown →